Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

NCT ID: NCT00880542

Last Updated: 2020-08-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-08-31

Brief Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with ifosfamide may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving sorafenib together with ifosfamide and to see how well it works in treating patients with high-grade soft tissue sarcoma or bone sarcoma that can be removed by surgery.

Detailed Description

OBJECTIVES:

Primary

• Assess the safety, toxicity, and efficacy of neoadjuvant sorafenib tosylate and ifosfamide in patients with resectable high-grade soft tissue or bone sarcoma.

Secondary

• Assess the long-term efficacy or impact of therapy in these patients, in terms of the duration of local recurrence-free survival, distant recurrence-free survival, and disease-specific survival.

OUTLINE:

• Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days* for 3 courses.

NOTE: *Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration.

• Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery.
• Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy.

Conditions

Sarcoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sorafenib + Ifosfamide

• Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days* for 3 courses.

NOTE: *Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration.

• Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery.
• Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy.

Group Type: EXPERIMENTAL

sorafenib

Intervention Type: DRUG

Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.

Ifosfamide

Intervention Type: DRUG

Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.

Interventions

sorafenib

Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.

Intervention Type: DRUG

Ifosfamide

Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Pathologically confirmed high grade sarcoma of the soft tissue or bone
• participants Identified as a proper candidate for ifosfamide-based neoadjuvant therapy
• candidates must have operable disease for which a resection is planned
• ECOG performance status 0-1
• Hemoglobin ≥ 9.0 g/dL
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement)
• INR < 1.5 or PT/PTT normal.Concurrent anticoagulation therapy with warfarin or heparin allowed
• Creatinine ≤ 1.5 times ULN
• women of childbearing potential must have negative pregnancy test performed within 7 days prior to start of treatment.
• Fertile patients must use effective contraception during and for ≥ 2 weeks after completion of study therapy.
• A signed informed consent must be obtained prior to any study specific procedures.

Exclusion Criteria

• known HIV infection
• chronic hepatitis B or C infection
• clinically active serious infection > CTCAE grade 2
• NYHA class III or IV congestive heart failure
• unstable angina (i.e., anginal symptoms at rest) or new onset angina within the past 3 months
• myocardial infarction within the past 6 months
• cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
• uncontrolled hypertension (i.e., systolic blood pressure [BP] > 150 mm Hg or diastolic BP > 90 mm Hg) despite optimal medical management
• thrombolic or embolic events (e.g., cerebrovascular accident, including transient ischemic attacks) within the past 6 months
• pulmonary hemorrhage or bleeding event ≥ CTCAE grade 2 within the past 4 weeks
• other hemorrhage or bleeding event ≥ CTCAE grade 3 within the past 4 weeks
• Any condition that would impair the ability to swallow whole pills
• malabsorption problem
• Any known severe hypersensitivity to sorafenib tosylate or any of its excipients
• known or suspected allergy to sorafenib tosylate or any agent given in this study
• serious nonhealing wound, ulcer, or bone fracture
• evidence or history of bleeding diathesis or coagulopathy
• significant traumatic injury within the past 4 weeks
• major surgery or open biopsy within 4 weeks of starting treatment
• Concomitant St. John's wort or rifampin
• KNown brain metastases. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastases.
• any condition that impairs patients' ability to swallow pills
• any malabsorption problem

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jonsson Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

William Tap, MD

Role: PRINCIPAL_INVESTIGATOR

Jonsson Comprehensive Cancer Center

Locations

Jonsson Comprehensive Cancer Center at UCLA

Los Angeles, California, United States

Countries

United States

Other Identifiers

UCLA-0704086

Identifier Type: -

Identifier Source: secondary_id

BAYER-UCLA-0704086

Identifier Type: -

Identifier Source: secondary_id

ONYX-UCLA-0704086

Identifier Type: -

Identifier Source: secondary_id

CDR0000633030

Identifier Type: -

Identifier Source: org_study_id